Coagulation Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 4400
$ 6600
$ 8900

Coagulation, also known as blood clotting, is a vital physiological process that helps prevent excessive bleeding and maintain hemostasis. It involves a complex mechanism of action where various clotting factors and platelets work together to form a clot, sealing off damaged blood vessels. Coagulation is used to treat a range of disease indications, including hemophilia, von Willebrand disease, deep vein thrombosis, pulmonary embolism, and disseminated intravascular coagulation. According to the World Health Organization (WHO), hemophilia affects approximately 1 in 10,000 people in Europe, with more than 400,000 individuals diagnosed worldwide. In the United States, around 20,000 people are estimated to have hemophilia, as reported by the Centers for Disease Control and Prevention (CDC). Deep vein thrombosis and pulmonary embolism collectively affect around 1 to 2 per 1,000 individuals per year in Europe, as per statistics from the European Society of Cardiology.

The growth drivers of the Coagulation market include increasing awareness about coagulation disorders, a growing geriatric population, and rising incidences of cardiovascular diseases. Technological advancements in diagnostic tools and treatment options, such as point-of-care testing devices and novel anticoagulants, further fuel market growth. Companies such as Takeda, ISU Abxis, Pfizer, Chiesi, AstraZeneca, United Therapeutics Corp, Octapharma, Sanofi, Regeneron, UCB, Roche, Idorsia, ImmunityBio, uniQure, Apellis, SZGIMI, Ligand, Bayer, Ultragenyx, Ascension Healthcare, and CSL Behring cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, UCB is currently conducting a clinical trial of the drug RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria.

Key Developments

  • In June 2023, FDA approved an IND application for Clopidogrel nano-emulsion in coronary artery disease (CAD)
  • In June 2023, AstraZeneca got Preregistration Soliris in Myasthenia gravis (In children, In adolescents, Treatment-experienced) in European Union

Approved Coagulation molecules

  • Clopidogrel
  • Ticagrelor
  • Prasugrel
  • Cilostazol
  • Soliris (eculizumab)
  • NovoSeven (eptacog alfa)
  • Advate (octocog alfa)
  • Clotinab (abciximab)
  • Treprostinil
  • Xyntha (moroctocog alfa)
  • Kengreal (cangrelor)
  • Ultomiris IV (ravulizumab-cwvz IV)
  • BeneFix (nonacog alfa)
  • Tyvaso (treprostinil)
  • Kogenate FS (octocog alfa sucrose formulation)
  • Eloctate (efraloctocog alfa)
  • NovoEight (turoctocog alfa)
  • Adynovate (rurioctocog alfa pegol)
  • Rupex (rupatadine)
  • Feiba (human plasma derived anti-inhibitor coagulant complex)
  • Gohibic (vilobelimab)
  • Nuwiq (simoctocog alfa)
  • Cablivi (caplacizumab)
  • Empaveli (pegcetacoplan SC)
  • bezafibrate
  • Alprolix (eftrenonacog alfa)
  • Jivi (damoctocog alfa pegol)
  • Esperoct (turoctocog alfa pegol)
  • NovoThirteen (catridecacog)
  • Wilate (human factor VIII)
  • Rebinyn (nonacog beta pegol)
  • Coversin SC (nomacopan SC)
  • Kovaltry (octocog alfa)
  • Rixubis (nonacog gamma)
  • Biostate (factor VIII)
  • Haemate-P (human plasma derived von Willebrand factor
  • Ixinity (trenonacog alfa)
  • Optivate (factor VIII)
  • Tavneos (avacopan)
  • Zimura (avacincaptad pegol)
  • Idelvion (albutrepenonacog alfa)
  • Obizur (susoctocog alfa)
  • Octanate (human Factor VIII
  • Vonvendi (vonicog alfa)
  • Alphanate (human plasma derived von Willebrand factor)
  • Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl)
  • Disgren (triflusal)

Coagulation Pipeline Molecules

  • Danicopan (ALXN2040)
  • Milvexian (BMS-986177)
  • Vemircopan (ALXN2050)
  • Pozelimab (REGN3918)
  • Zilucoplan (RA101495)
  • Cemdisiran (ALN-CC5)
  • Mim8
  • Crovalimab (RG6107)
  • Selatogrel (ACT-246475)
  • Tesidolumab (LFG316)
  • Abelacimab (MAA868)
  • Egaptivon pegol (ARC1779)
  • asundexian (BAY 2433334)
  • Lampalizumab (RG7417)
  • SHR2285
  • Avdoralimab (IPH5401)
  • Fidanacogene elaparvovec (PF-06838435)
  • Pelecopan (BCX9930)
  • KP104
  • MK-2060
  • PPY988
  • STSA-1002
  • TB-402
  • Bentracimab (PB2452)
  • Elinogrel (PRT-060128)
  • Marzeptacog alfa (CB 813d)
  • Treprostinil palmitil inhalation (INS1009)
  • AMY-101
  • Beraprost 314d (esuberaprost)
  • FRSW107
  • JNJ-81201887

Clinical Activity and Development of Coagulation

In the Coagulation space, more than 20 companies are conducting more than 400 clinical trials in this category of drugs. For instance,

  • In June 2023, AstraZeneca released Updated adverse events data from a phase III trial of Soliris in Myasthenia gravis
  • In June 2023, the Committee for Medicinal Products for Human Use (CHMP) of the EMA recommended expanded use of eculizumab for Myasthenia gravis (In children, In adolescents, Treatment experienced) in the European Union

Product Name

Total Studies

Danicopan (ALXN2040)

29

Milvexian (BMS-986177)

26

Vemircopan (ALXN2050)

18

Pozelimab (REGN3918)

14

Zilucoplan (RA101495)

14

Cemdisiran (ALN-CC5)

13

Mim8

9

Crovalimab (RG6107)

9

Selatogrel (ACT-246475)

9

Tesidolumab (LFG316)

9

Abelacimab (MAA868)

8

Egaptivon pegol (ARC1779)

8

Asundexian (BAY 2433334)

7

Lampalizumab (RG7417)

7

SHR2285

6

Avdoralimab (IPH5401)

6

Fidanacogene elaparvovec (PF-06838435)

6

Pelecopan (BCX9930)

6

KP104

5

MK-2060

5

Target Indication Analysis of Coagulation

The target indication for coagulation encompasses a range of medical conditions, including hemophilia, von Willebrand disease, deep vein thrombosis, pulmonary embolism, and disseminated intravascular coagulation. Coagulation disorders can lead to life-threatening complications such as uncontrolled bleeding or thrombosis. Accurate diagnosis and monitoring of coagulation parameters, such as prothrombin time, activated partial thromboplastin time, and fibrinogen levels, are essential for effective management and personalized treatment strategies. Coagulation therapies involve the administration of clotting factors, anticoagulants, or antiplatelet drugs to restore or regulate the coagulation process, thereby preventing or resolving coagulation-related abnormalities and improving patient outcomes.

Frequently Asked Questions

Coagulation drugs are used in the management of hemophilia, von Willebrand disease, deep vein thrombosis, pulmonary embolism, and disseminated intravascular coagulation.

The growth drivers of the Coagulation market include increasing awareness about coagulation disorders, a growing geriatric population, and rising incidences of cardiovascular diseases. Technological advancements in diagnostic tools and treatment options, such as point-of-care testing devices and novel anticoagulants, further fuel market growth.

The major players in this space are Takeda, ISU Abxis, Pfizer, Chiesi, AstraZeneca, United Therapeutics Corp, Octapharma, Sanofi, Regeneron, UCB, Roche, Idorsia, ImmunityBio, uniQure, Apellis, SZGIMI, Ligand, Bayer, Ultragenyx, Ascension Healthcare, and CSL Behring.

The coagulation market faces restraints due to increasing competition among manufacturers and the availability of alternative treatment options. Additionally, stringent regulatory requirements and the high cost associated with coagulation testing devices pose challenges to market growth.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Adjacent Markets